Authors: Van Dalen, A Favier, J Baumgartner, L Hasholzner, U De Bruijn, H Dobbler, D Dombi, VH Fink, D Giai, M Mcging, P Harlozinska, A Kainz, C Markowska, J Molina, R Sturgeon, C Bowman, A Einarsson, R

Citation: A. Van Dalen et al., Serum levels of CA 125 and TPS during treatment of ovarian cancer, ANTICANC R, 20(6D), 2000, pp. 5107-5108

Authors: van Dalen, A Favier, J Burges, A Hasholzner, U de Bruijn, HWA Dobler-Girdziunaite, D Dombi, VH Fink, D Giai, M McGing, P Harlozinska, A Kainz, C Markowska, J Molina, R Sturgeon, C Bowman, A Einarsson, R

Citation: A. Van Dalen et al., Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients, GYNECOL ONC, 79(3), 2000, pp. 444-450

Authors: Hasholzner, U Stieber, P Zimmermann, A Burges, A Hofmann, K Schmitt, UM Schmeller, N Schalhorn, A

Citation: U. Hasholzner et al., Nuclear mitotic apparatus protein (NuMA) in benign and malignant diseases, ANTICANC R, 19(4A), 1999, pp. 2415-2420

Authors: Hasholzner, U Stieber, P Reiter, W Zimmermann, A Hofmann, K Schalhorn, A

Citation: U. Hasholzner et al., CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer, ANTICANC R, 19(4A), 1999, pp. 2477-2480

Authors: Van Dalen, A Favier, J Baumgartner, L Hasholzner, U De Bruijn, H Dobbler, D Dombi, VH Fink, D Giai, M McGing, P Harlozinska, A Kainz, C Markowska, J Molina, R Sturgeon, C Einarsson, R

Citation: A. Van Dalen et al., Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients, ANTICANC R, 19(4A), 1999, pp. 2523-2526